Science Explorer Back to mapMap
Discussion
Researcher · Eisai (Japan) · Japan

Kentaro Iso

Kentaro Iso publishes mostly in Organic Chemistry, Molecular Biology and Oncology, on topics such as Synthetic Organic Chemistry Methods, Protein Degradation and Inhibitors and Marine Sponges and Natural Products.

ORCID 0000-0001-5417-3642 OpenAlex
World rank
#1,465,719
of 7,710,434 ranked researchers
Rank in Japan
#23,132
of 383,136
Works
42
Citations
806
Citations per work
19.2
h-index
13
i10-index 14Top 45% in Organic Chemistry
Kentaro Iso

What does Kentaro Iso research?

Kentaro Iso's work is mostly in Chemistry (42%), Biochemistry, Genetics and Molecular Biology (36%), Medicine (14%).

Physical Sciences: 18 works · 42.4% of their workChemistry: 18 works · 42.4% of their workOrganic Chemistry: 18 works · 42.4% of their workLife Sciences: 15 works · 36.5% of their workBiochemistry, Genetics and Molecular Biology: 15 works · 36.5% of their workMolecular Biology: 10 works · 23.5% of their workBiotechnology: 3 works · 7.1% of their workCancer Research: 2 works · 5.9% of their workHealth Sciences: 6 works · 14.1% of their workMedicine: 6 works · 14.1% of their workOncology: 4 works · 9.4% of their workPharmacology: 2 works · 4.7% of their workEverything else: 3 works · 7.0% of their workTHEIR WORKKentaro Iso42works
Life Sciences36%Physical Sciences42%Health Sciences14%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Chemistry1842.4%
    1. Biochemistry, Genetics and Molecular Biology1536.5%
    1. Medicine614.1%
  4. Everything else37.0%
  1. 1Organic Chemistry42% of their works
  2. 2Molecular Biology24% of their works
  3. 3Oncology9% of their works
  4. 4Biotechnology7% of their works
  5. 5Cancer Research6% of their works
  6. 6Pharmacology5% of their works

Research topics

Which keywords describe Kentaro Iso's research?

The keywords of their largest research topics: Asymmetric Synthesis, Olefin Metathesis, Pharmacology, Ruthenium Catalysts, BET Bromodomains, PROTACs, Ecteinascidin and Green Chemistry.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 18 words, with their numbers
  1. Asymmetric Synthesis143 topics
  2. Olefin Metathesis101 topic
  3. Pharmacology102 topics
  4. Ruthenium Catalysts101 topic
  5. BET Bromodomains71 topic
  6. PROTACs71 topic
  7. Ecteinascidin51 topic
  8. Green Chemistry51 topic
  9. Marine Natural Products51 topic
  10. Multicomponent Reactions51 topic
  11. Sponge-Associated Microorganisms51 topic
  12. Tetrahydroisoquinoline51 topic
  13. Alkaloids41 topic
  14. Amaryllidaceae41 topic
  15. Enantioselective Reactions41 topic
  16. Fibroblast Activation Protein41 topic
  17. Organocatalysis41 topic
  18. Tumor Microenvironment41 topic

Where does Kentaro Iso work?

Kentaro Iso's main affiliation in the publication record is Eisai (Japan), Japan.

How many publications and citations does Kentaro Iso have?

OpenAlex counts 42 works and 806 citations for Kentaro Iso, an h-index of 13, ranking #1,465,719 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Kentaro Iso. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.